Vivos Therapeutics Shares Rise After Medicare Approval for VidaSleep

Dow Jones

2025/07/02

By Chris Wack

Vivos Therapeutics shares were 24% higher, at $3.91, after the company said its VidaSleep oral appliance was approved by the Centers for Medicare & Medicaid Services Pricing, Data Analysis and Coding contractor for treatment of mild to moderate obstructive sleep apnea and snoring in adults.

The Littleton, Colo., medical-technology company said on Tuesday that VidaSleep features its Unilateral Bite Block technology, which is patented and has been cleared by the Food and Drug Administration.

Medicare coverage opens the door to commercial payers that follow CMS guidelines, increasing Vivos' addressable market, Vivos said.

With this approval, Vivos said, VidaSleep joins its mmRNA on the Pricing, Data Analysis and Coding list of covered oral appliances, unlocking access for millions of Medicare beneficiaries.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

July 01, 2025 13:58 ET (17:58 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2548881360"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548881360\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548881360?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-02 01:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548881360","market":"sg","top_or_hot":-1,"title":"Vivos Therapeutics Shares Rise After Medicare Approval for VidaSleep","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/VVOS\">Vivos Therapeutics</a> shares were 24% higher, at $3.91, after the company said its VidaSleep oral appliance was approved by the Centers for Medicare &amp; Medicaid Services Pricing, Data Analysis and Coding contractor for treatment of mild to moderate obstructive sleep apnea and snoring in adults. \n</p>\n<p>\n  The Littleton, Colo., medical-technology company said on Tuesday that VidaSleep features its Unilateral Bite Block technology, which is patented and has been cleared by the Food and Drug Administration. \n</p>\n<p>\n  Medicare coverage opens the door to commercial payers that follow <a href=\"https://laohu8.com/S/8A8.SI\">CMS</a> guidelines, increasing Vivos' addressable market, Vivos said. \n</p>\n<p>\n  With this approval, Vivos said, VidaSleep joins its mmRNA on the Pricing, Data Analysis and Coding list of covered oral appliances, unlocking access for millions of Medicare beneficiaries. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 01, 2025 13:58 ET (17:58 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vivos Therapeutics Shares Rise After Medicare Approval for VidaSleep</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVivos Therapeutics Shares Rise After Medicare Approval for VidaSleep\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-02 01:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/VVOS\">Vivos Therapeutics</a> shares were 24% higher, at $3.91, after the company said its VidaSleep oral appliance was approved by the Centers for Medicare &amp; Medicaid Services Pricing, Data Analysis and Coding contractor for treatment of mild to moderate obstructive sleep apnea and snoring in adults. \n</p>\n<p>\n  The Littleton, Colo., medical-technology company said on Tuesday that VidaSleep features its Unilateral Bite Block technology, which is patented and has been cleared by the Food and Drug Administration. \n</p>\n<p>\n  Medicare coverage opens the door to commercial payers that follow <a href=\"https://laohu8.com/S/8A8.SI\">CMS</a> guidelines, increasing Vivos' addressable market, Vivos said. \n</p>\n<p>\n  With this approval, Vivos said, VidaSleep joins its mmRNA on the Pricing, Data Analysis and Coding list of covered oral appliances, unlocking access for millions of Medicare beneficiaries. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 01, 2025 13:58 ET (17:58 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VVOS","symbol_name":"Vivos Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2548881360","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548881360","pubTimestamp":1751392680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Vivos Therapeutics shares were 24% higher, at $3.91, after the company said its VidaSleep oral appliance was approved by the Centers for Medicare & Medicaid Services Pricing, Data Analysis and Coding contractor for treatment of mild to moderate obstructive sleep apnea and snoring in adults.The Littleton, Colo., medical-technology company said on Tuesday that VidaSleep features its Unilateral Bite Block technology, which is patented and has been cleared by the Food and Drug Administration.Medicare coverage opens the door to commercial payers that follow CMS guidelines, increasing Vivos' addressable market, Vivos said.With this approval, Vivos said, VidaSleep joins its mmRNA on the Pricing, Data Analysis and Coding list of covered oral appliances, unlocking access for millions of Medicare beneficiaries.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VVOS":"Vivos Therapeutics","BK4196":"保健护理服务"},"translate_title":"Vivos Therapeutics股价在Medicare批准VidaSleep后上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VVOS":1},"content_text":"By Chris Wack \n\n\n \n\n\nVivos Therapeutics shares were 24% higher, at $3.91, after the company said its VidaSleep oral appliance was approved by the Centers for Medicare & Medicaid Services Pricing, Data Analysis and Coding contractor for treatment of mild to moderate obstructive sleep apnea and snoring in adults. \n\n\n  The Littleton, Colo., medical-technology company said on Tuesday that VidaSleep features its Unilateral Bite Block technology, which is patented and has been cleared by the Food and Drug Administration. \n\n\n  Medicare coverage opens the door to commercial payers that follow CMS guidelines, increasing Vivos' addressable market, Vivos said. \n\n\n  With this approval, Vivos said, VidaSleep joins its mmRNA on the Pricing, Data Analysis and Coding list of covered oral appliances, unlocking access for millions of Medicare beneficiaries. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 01, 2025 13:58 ET (17:58 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}